US 12,435,079 B2
Bruton's tyrosine kinase inhibitors
Xibin Liao, Edison, NJ (US); and Yubin Lv, Hangzhou (CN)
Assigned to Xibin Liao, Edison, NJ (US)
Appl. No. 17/423,736
Filed by Xibin Liao, Edison, NJ (US)
PCT Filed Jan. 17, 2020, PCT No. PCT/US2020/014214
§ 371(c)(1), (2) Date Jul. 16, 2021,
PCT Pub. No. WO2020/150681, PCT Pub. Date Jul. 23, 2020.
Claims priority of provisional application 62/794,284, filed on Jan. 18, 2019.
Prior Publication US 2022/0064162 A1, Mar. 3, 2022
Int. Cl. C07D 487/04 (2006.01); C07D 471/04 (2006.01)
CPC C07D 471/04 (2013.01) [C07D 487/04 (2013.01)] 2 Claims
 
1. A compound of Formula (I) or (II) having the following structure, a tautomer thereof, a pharmaceutical acceptable solvate thereof, or a pharmaceutical acceptable prodrug thereof:

OG Complex Work Unit Chemistry
wherein:
A is C(NH2) or CH, B is N, G is CH, and D is CH;
R2 is independently hydrogen, and y is an integer from 0 to 5; and y is an integer from 0 to 5;
M is

OG Complex Work Unit Chemistry
X is —O— or —CH2—NH—CO—; and
E is

OG Complex Work Unit Chemistry